Streetbeat News

Analyst Ratings

CSX

CSX Corporation reported Q2 earnings in line with expectations, but sales missed estimates. The company's shares fell 4.5% in pre-market trading. Following the earnings announcement, Citigroup, Susquehanna, and BMO Capital adjusted their price targets on CSX.

Portfolio Pulse from Lisa Levin

July 21, 2023 | 12:14 pm

MAN

Goldman Sachs analyst George Tong maintains a Sell rating on ManpowerGroup (NYSE:MAN) and raises the price target from $69 to $79.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:14 pm

SIRI

Sirius XM shares are trading lower after multiple firms downgraded their rating on the stock following yesterday's rally.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:14 pm

KEY

Goldman Sachs analyst Ryan Nash maintains a Buy rating on KeyCorp (NYSE:KEY) and raises the price target from $11.5 to $13.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:13 pm

NVTA

Goldman Sachs analyst Matthew Sykes has maintained a 'Sell' rating on Invitae (NYSE:NVTA) and lowered the price target from $1.5 to $1.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:12 pm

WGS

Goldman Sachs analyst Matthew Sykes has maintained a Neutral rating on GeneDx Hldgs (NASDAQ:WGS) and lowered the price target from $9 to $8.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:11 pm

FITB

Wedbush analyst David Chiaverini maintains an Outperform rating on Fifth Third Bancorp (NASDAQ:FITB) and raises the price target from $32 to $33.

Portfolio Pulse from richadhand@benzinga.com

July 21, 2023 | 12:11 pm

EWBC

Wedbush analyst David Chiaverini maintains a Neutral rating on East West Bancorp (NASDAQ:EWBC) and raises the price target from $55 to $65.

Portfolio Pulse from richadhand@benzinga.com

July 21, 2023 | 12:10 pm

FITB

Goldman Sachs analyst Ryan Nash maintains a Buy rating on Fifth Third Bancorp (NASDAQ:FITB) and raises the price target from $30 to $34.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:10 pm

EXAS

Goldman Sachs analyst Matthew Sykes has maintained a 'Buy' rating on Exact Sciences (NASDAQ:EXAS) and raised the price target from $85 to $110.

Portfolio Pulse from Benzinga Newsdesk

July 21, 2023 | 12:09 pm